ONCONOVA THERAPEUTICS INC (ONTX) Stock Price & Overview
NASDAQ:ONTX • US68232V8019
Current stock price
The current stock price of ONTX is 0.9953 USD. Today ONTX is down by -0.47%. In the past month the price increased by 7.02%. In the past year, price increased by 42.19%.
ONTX Key Statistics
- Market Cap
- 20.901M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.97
- Dividend Yield
- N/A
ONTX Stock Performance
ONTX Stock Chart
ONTX Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to ONTX. When comparing the yearly performance of all stocks, ONTX is one of the better performing stocks in the market, outperforming 91.64% of all stocks.
ONTX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ONTX. While ONTX seems to be doing ok healthwise, there are quite some concerns on its profitability.
ONTX Earnings
ONTX Forecast & Estimates
9 analysts have analysed ONTX and the average price target is 8.5 USD. This implies a price increase of 754.01% is expected in the next year compared to the current price of 0.9953.
For the next year, analysts expect an EPS growth of -7.23% and a revenue growth 2.54% for ONTX
ONTX Groups
Sector & Classification
ONTX Financial Highlights
Over the last trailing twelve months ONTX reported a non-GAAP Earnings per Share(EPS) of -0.97. The EPS decreased by -21.25% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -74.67% | ||
| ROE | -139.07% | ||
| Debt/Equity | 0 |
ONTX Ownership
ONTX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.51 | 854.108B | ||
| JNJ | JOHNSON & JOHNSON | 18.46 | 564.915B | ||
| MRK | MERCK & CO. INC. | 23.38 | 285.462B | ||
| PFE | PFIZER INC | 9.22 | 154.837B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.5 | 120.381B | ||
| ZTS | ZOETIS INC | 17.3 | 50.25B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.68 | 27.966B | ||
| VTRS | VIATRIS INC | 5.89 | 16.314B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.51 | 11.5B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.421B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.081B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.929B | ||
| CORT | CORCEPT THERAPEUTICS INC | 85.07 | 4.676B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ONTX
Company Profile
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. The company is headquartered in Newtown, Pennsylvania and currently employs 16 full-time employees. The company went IPO on 2013-07-25. The company has molecularly targeted agents designed to disrupt specific cellular pathways for cancer cell proliferation. The company has the two clinical-stage programs: narazaciclib (ON 123300), which is a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib administered alone or in combination for the treatment of solid tumors. Narazaciclib targets cyclin-dependent kinases (CDK's), AMPK related protein kinase 5 (ARK5), and colony-stimulating factor 1 receptor (CSF1R) at low nM concentrations as well as other tyrosine kinases. The company is also engaged in supporting investigator-initiated studies (IIS) that explores the use of rigosertib for cancers driven by mutated K-Ras genes, including a Phase I/IIa study of rigosertib with a PD-1 inhibitor.
Company Info
IPO: 2013-07-25
ONCONOVA THERAPEUTICS INC
375 Pheasant Run
Newtown PENNSYLVANIA 18940 US
CEO: Steven M. Fruchtman
Employees: 16
Phone: 12677593681
ONCONOVA THERAPEUTICS INC / ONTX FAQ
Can you describe the business of ONCONOVA THERAPEUTICS INC?
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the identification and development of oncology therapeutics. The company is headquartered in Newtown, Pennsylvania and currently employs 16 full-time employees. The company went IPO on 2013-07-25. The company has molecularly targeted agents designed to disrupt specific cellular pathways for cancer cell proliferation. The company has the two clinical-stage programs: narazaciclib (ON 123300), which is a multi-targeted kinase inhibitor in solid tumors and hematological malignancies as a single agent or in combination with other anti-cancer therapies; and rigosertib administered alone or in combination for the treatment of solid tumors. Narazaciclib targets cyclin-dependent kinases (CDK's), AMPK related protein kinase 5 (ARK5), and colony-stimulating factor 1 receptor (CSF1R) at low nM concentrations as well as other tyrosine kinases. The company is also engaged in supporting investigator-initiated studies (IIS) that explores the use of rigosertib for cancers driven by mutated K-Ras genes, including a Phase I/IIa study of rigosertib with a PD-1 inhibitor.
What is the current price of ONTX stock?
The current stock price of ONTX is 0.9953 USD. The price decreased by -0.47% in the last trading session.
What is the dividend status of ONCONOVA THERAPEUTICS INC?
ONTX does not pay a dividend.
What is the ChartMill technical and fundamental rating of ONTX stock?
ONTX has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Is ONCONOVA THERAPEUTICS INC (ONTX) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ONTX.
When does ONCONOVA THERAPEUTICS INC (ONTX) report earnings?
ONCONOVA THERAPEUTICS INC (ONTX) will report earnings on 2024-05-13, after the market close.